Akebia Therapeutics Inc
NASDAQ:AKBA

Watchlist Manager
Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc
NASDAQ:AKBA
Watchlist
Price: 2.92 USD 2.1% Market Closed
Market Cap: 764.4m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+24%
Revenue
Forecast
+13%
Operating Income
Forecast
+19%
Net Income
Forecast
+10%

Wall Street
Price Targets

AKBA Price Targets Summary
Akebia Therapeutics Inc

Wall Street analysts forecast AKBA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AKBA is 7.52 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

AKBA Lowest Forecast
Wall Street Target
6.06 USD
108% Upside
AKBA Average Forecast
Wall Street Target
7.52 USD
158% Upside
AKBA Highest Forecast
Wall Street Target
10.5 USD
260% Upside
Lowest
Price Target
6.06 USD
108% Upside
Average
Price Target
7.52 USD
158% Upside
Highest
Price Target
10.5 USD
260% Upside
Akebia Therapeutics Inc Competitors:
Price Targets
BMRN
Biomarin Pharmaceutical Inc
69% Upside
PBYI
Puma Biotechnology Inc
63% Upside
J
600201
Jinyu Bio-Technology Co Ltd
13% Upside
IDYA
IDEAYA Biosciences Inc
171% Upside
BMRN
Biomarin Pharmaceutical Inc
69% Upside
PBYI
Puma Biotechnology Inc
63% Upside
J
600201
Jinyu Bio-Technology Co Ltd
13% Upside
IDYA
IDEAYA Biosciences Inc
171% Upside
AGIO
Agios Pharmaceuticals Inc
87% Upside
688177
Bio-Thera Solutions Ltd
1% Upside
300685
Amoy Diagnostics Co Ltd
53% Upside
NBIX
Neurocrine Biosciences Inc
30% Upside

Revenue
Forecast

Revenue Estimate
Akebia Therapeutics Inc

For the last 8 years the compound annual growth rate for Akebia Therapeutics Inc's revenue is 79%. The projected CAGR for the next 3 years is 31%.

79%
Past Growth
31%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Akebia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Akebia Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-46%
Average Miss
What are analyst estimates?

See Also

Summary
AKBA intrinsic value, competitors valuation, and company profile.
DCF Valuation
AKBA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AKBA stock valuation using valuation multiples.
Wall Street Estimates
AKBA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AKBA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is AKBA's stock price target?
Price Target
7.52 USD

According to Wall Street analysts, the average 1-year price target for AKBA is 7.52 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

What is Akebia Therapeutics Inc's Revenue forecast?
Projected CAGR
31%

For the last 8 years the compound annual growth rate for Akebia Therapeutics Inc's revenue is 79%. The projected CAGR for the next 3 years is 31%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 257,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.